• Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a highly collegial group that is dedicated to the pursuit of excellence and advancement of critical care research in Canada.
  • Canadian Critical Care Trials Group
    The CCCTG has are more than 30 research programs underway and over 100 peer-reviewed publications to its credit, with direct impact on clinical practice in critical care.
  • Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a national organization of more than 300 individuals with research interests in the management of the critically ill patient.
  • Canadian Critical Care Trials Group
    Endorsement by the CCCTG communicates our full commitment to ensure that the work is undertaken in a rigorous and ethical manner, and communicated in a timely and effective way.
Members

Nicolay Ferrari

“I am very honoured and delighted to have the opportunity to serve the Canadian Critical Care Trial Group community as the new Executive Director of the CCCTG. I look forward to building on the rich history of the group and outstanding clinical research. I am dedicated in working with the Chair, Dr. Paul Hébert, and the Executive Committee to successfully advance the strategic agenda to strengthen the key activities and support the growth of the group while maintaining the CCCTG core values of science excellence and collegiality to improve the outcomes of critically ill patients.”

Dr. Nicolay Ferrari completed his graduate studies at the Université de Montréal in 1999. He then pursued his post-doctoral work at the Dana-Farber Cancer Institute of the Harvard Medical School (Boston MA) and at the National Cancer Institute of the National Institutes of Health (Bethesda MD) developing anti-angiogenic gene therapy approaches and the use of neuronal stem cells as delivery vehicles of therapeutic genes for the treatment of brain tumors. Dr. Ferrari recently completed a Graduate Diploma in Management and Business from McGill in 2012. Following his postdoctoral studies, he spent 12 years in the biotechnology sector, first at Celmed Biosciences as Group Leader and then at Topigen Pharmaceuticals. At Topigen, as Director Pharmacology, he provided leadership for discovery and preclinical research activities that lead to the development of three novel anti-inflammatory drug candidates for the treatment of respiratory diseases, one currently in Phase 2 for the treatment of asthma. Since 2011, Dr. Ferrari is a Lecturer at the Department of Pharmacology at the Université de Sherbrooke. Just prior to joining the Canadian Critical Care Trial Group, Dr. Ferrari was the Assistant Director of the Institute of Cancer Research of the Canadian Institutes of Health Research where he assisted the development of novel funding opportunities and public-private partnerships.